Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited ...

YolTech's gene therapy is intended as a one-time life-long cure for patients living with PH1, which can lead to kidney ...

Regeneron’s gene therapy, dubbed DB-OTO, is a cell-selective AAV gene therapy for children with hearing loss stemming from a ...

The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...

A vast search of natural diversity has led scientists at MIT’s McGovern Institute and the Broad Institute of MIT and Harvard ...

CRISPR technology, driven by Cas9, redefines gene editing, facilitating targeted DNA modifications that advance genetic ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

ElevateBio is seeking out partnerships for its lead gene therapy after the construct reduced the levels of a toxic protein in ...

YolTech Therapeutics reports positive clinical data for YOLT-203, an in vivo gene editing therapy for primary hyperoxaluria type 1: Shanghai, China Wednesday, February 26, 2025, 1 ...

A study led by UMass Chan researchers demonstrated that a gene therapy to correct a mutation that causes maple syrup urine ...